Use of anti-platelet agents after XXXX .

@entity1 @entity932 @entity548 @entity1423 @entity715 @entity130
OBJECTIVE: To evaluate the risk of @entity548 associated with starting @entity1423 ( @entity1423 ) after acute @entity932 ( @entity932 ) and to examine the frequency of @entity715 . @entity1 AND METHODS: We retrospectively identified all @entity1 admitted to our institution with @entity932 that received @entity1423 during their initial hospitalization over a three-year period. We reviewed their demographics, hospital course, clinical indication and timing for initiation of @entity1423 , and complications. RESULTS: A total of 222 @entity1 were identified. The median age and Injury Severity Score (ISS) was 61 and 21, respectively. Fifty (23%) @entity1 required neurosurgical procedures. APTs were initiated due to a history of @entity1423 use in 91 @entity1 (41%) and blunt @entity130 in 86 @entity1 (38.6%). The median time from @entity1423 was 4 days. Immediate complications including new or worsening @entity548 occurred in 1 (<1%) @entity1 . Delayed @entity548 occurred in 6 (4.7%) @entity1 . @entity715 events occurred in 21 (9.4%) @entity1 prior to starting @entity1423 . Thirteen (5.8%) of these were potentially preventable. CONCLUSION: The risk of immediate and delayed @entity932 from initiating @entity1423 after @entity932 must be weighed against the morbidity of delaying indicated @entity715 . Our initial data indicates that @entity548 are infrequent, and @entity715 can have significant clinical consequences. Our retrospective review provides the first rates of complications for this @entity1 population.
